WuXi AppTec Co (603259.SS) Stock Price
WuXi AppTec Co Price
Revenue has compounded at 24.3% per year over the past 11 years to 45.46 B CNY. Earnings per share have grown at 40.3% per year over the last 11 years. WuXi AppTec Co's net margin stands at 42.1%, up from 22.3% several years earlier. WuXi AppTec Co currently offers a dividend yield of about 1.10%. The payout ratio is around 21% of earnings. The dividend has grown at 37.7% per year over the past 6 years. Analysts set a median price target of 132.60 CNY, implying 13.3% below the current price. Of 25 analysts, 23 rate the stock a buy — an overall Buy consensus.
WuXi AppTec Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
WuXi AppTec Co business model & stock analysis
Frequently asked questions about WuXi AppTec Co
WuXi AppTec Co Ltd is primarily present in multiple countries and regions globally. Some of the key locations where the company has a significant presence include China, the United States, Germany, the United Kingdom, Japan, and Singapore. With a wide network of operations and collaborations, WuXi AppTec has established itself as a leading global pharmaceutical, biotechnology, and medical device company. Through its extensive presence and expertise, the company aims to provide innovative solutions and support to its clients in the healthcare industry across various markets.
The business model of WuXi AppTec Co Ltd is focused on providing comprehensive R&D services and integrated platform solutions for the pharmaceutical, biotechnology, and medical device industries. With a customer-centric approach, WuXi AppTec offers a wide range of services, including discovery, development, and manufacturing of drugs and medical devices. By leveraging its expertise in research, development, and manufacturing, along with its global network of facilities and technologies, WuXi AppTec aims to enable its customers to accelerate the discovery and development of innovative therapies and improve the overall efficiency of the drug development process.
WuXi AppTec Co Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of WuXi AppTec Co Ltd in the market include Charles River Laboratories International Inc., Eurofins Scientific SE, LabCorp, and PPD Inc.
WuXi AppTec Co Ltd is a leading global pharmaceutical and biotechnology company. Founded in China in 2000, the company has grown to become a key player in the life sciences industry. WuXi AppTec provides a wide range of services to support drug research and development, including laboratory testing, manufacturing, and biologics services. With a focus on innovation and quality, the company has established strategic collaborations with numerous pharmaceutical companies and research institutions worldwide. WuXi AppTec has received multiple recognitions and awards for its contributions to the healthcare industry. Today, it continues to expand its global presence and drive advances in drug discovery and development.
WuXi AppTec Co Ltd, a leading global pharmaceutical company, has achieved several significant milestones. The company has established itself as a leader in providing comprehensive and integrated research and development services to enable the discovery and development of innovative drugs. WuXi AppTec has expanded its global footprint and now operates in over 30 countries. The company has also made progress in advancing precision medicine and has collaborated with industry leaders to accelerate drug development. WuXi AppTec's commitment to innovation and collaboration has contributed to its success in becoming a trusted partner for the biopharmaceutical industry.
WuXi AppTec Co Ltd is a leading global pharmaceutical and biopharmaceutical open-access capability and technology platform company. It is committed to providing a broad portfolio of R&D and manufacturing services to help accelerate the discovery, development, and commercialization of innovative medicines. WuXi AppTec follows a corporate philosophy that emphasizes integrity, innovation, and collaboration. With a focus on quality and excellence, the company strives to create value for its customers, partners, and shareholders. WuXi AppTec Co Ltd's commitment to scientific expertise, customer-centricity, and continuous improvement reflects its dedication to advancing healthcare solutions and making a positive impact on society.
Analysts currently set an average price target of 130.66 CNY for the WuXi AppTec Co stock (median: 132.60 CNY), implying -14.6 % versus the latest price. The consensus is based on 25 analyst ratings.
25 analysts currently rate the WuXi AppTec Co stock: 23 recommend buying, 2 holding and 0 selling. For 2026, analysts expect WuXi AppTec Co to generate revenue of 60.11 B CNY and earnings per share of 9.18 CNY.
Converted at the current exchange rate, the WuXi AppTec Co share trades at 20.37 EUR (152.99 CNY).
The WuXi AppTec Co share (603259.SS) is listed on 1 stock exchanges, including: Shanghai (603259.SS).
WuXi AppTec Co Ltd is a global biotechnology and pharmaceutical company based in China. It was founded in 2000 and has built a wide portfolio of services in the areas of research and development, as well as manufacturing. The company is divided into various business divisions, including laboratory services, research and development, clinical trials, manufacturing and packaging, and services for biotech and pharmaceutical companies. It offers a range of services in laboratory services, such as chemical and biological analysis, preclinical safety and efficacy testing, as well as cellular and molecular biology. In the research and development area, the company works closely with its customers to develop new compounds and therapies. It also provides clinical trial services to test the effectiveness and safety of new drugs. Additionally, WuXi AppTec offers comprehensive manufacturing and packaging services and a range of consulting and support services. Overall, the company aims to support the research and development of new therapies and drugs, with a focus on quality and customer satisfaction.
The expected revenue of WuXi AppTec Co is 60.11 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of WuXi AppTec Co is 22.04 B CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of WuXi AppTec Co is currently 16.66. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the WuXi AppTec Co stock.
The price-to-sales ratio (P/S) of WuXi AppTec Co is currently 6.11. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the WuXi AppTec Co stock.
The Eulerpool Quality Score for WuXi AppTec Co is 7/10.
The ISIN of WuXi AppTec Co is CNE1000031K4. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of WuXi AppTec Co is 603259.SS. The ticker symbol is used to trade WuXi AppTec Co shares on the stock exchange.
WuXi AppTec Co stock
WuXi AppTec Co Peer Group
WuXi AppTec Co Ticker
WuXi AppTec Co FIGI
All fundamentals and in-depth analysis of WuXi AppTec Co
Our stock analysis for WuXi AppTec Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of WuXi AppTec Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.